AVB-500

December 20, 2019

Trial Seeks Participants to Study AVB-500 Plus Imfinzi in Platinum-resistant Ovarian Cancers

News

Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant epithelial ... Read more

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more